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OBJECTIVES The aim of our study was to verify the effect of oral administration of verapamil on atrial
electrophysiologic characteristics after cardioversion of persistent atrial fibrillation (AF) in
humans.
BACKGROUND Discordant findings have been reported regarding the efficacy of verapamil in preventing the
electrical remodeling induced by AF.
METHODS We determined the effective refractory periods (ERPs) at five pacing cycle lengths (300 to
700 ms) and in five right atrial sites after internal cardioversion of persistent AF (mean
duration 238.1 6 305.9 days) in 19 patients. Nine patients received oral verapamil
(240 mg/day) starting four weeks before the electrophysiologic study, whereas the other 10
patients were in pharmacologic washout.
RESULTS The mean ERPs were 202.0 6 22.7 ms in the washout group and 189.3 6 18.5 ms in the
verapamil group (p , 0.0001). The degree of adaptation of refractoriness to rate was similar
in the two groups (mean slope value in the washout group and verapamil group: 0.07 6 0.03
and 0.08 6 0.05, respectively), showing a normal or nearly normal adaptation to rate in the
majority of the paced sites in both groups. The mean ERP was slightly longer in the septum
than in the lateral wall and in the roof, both in the washout and verapamil groups.
CONCLUSIONS In patients with persistent AF, long-term administration of verapamil before internal
cardioversion resulted in 1) shortening of atrial ERPs; 2) no change in refractoriness
dispersion within the right atrium; and 3) no change in atrial ERP adaptation to rate. (J Am
Coll Cardiol 2000;36:2234–41) © 2000 by the American College of Cardiology
Several studies, both in animals and humans, have demon-
strated that high atrial rates, such as those determined either
by spontaneous and induced atrial fibrillation (AF) or by
rapid atrial pacing, lead to a shortening of the atrial effective
refractory period (ERP) (1–4). This condition could facil-
itate the maintenance of the arrhythmia and its recurrence
after sinus rhythm restoration. Subsequent experimental and
human studies have shown that this phenomenon, called
“electrical remodeling,” could be prevented by the adminis-
tration of verapamil (5–9). However, in two recent reports
(10,11), verapamil administered after the initiation of AF
actually caused a shortening of the local fibrillation cycle
length (a variable that is closely correlated with the atrial
ERP) in both the animal model and in patients with
persistent AF. This new finding is confounding and sug-
gests that the drug might reduce, rather than increase, the
chances of spontaneous termination of the arrhythmia and
facilitate, rather than prevent, its recurrence after cardiover-
sion.
However, the aforementioned studies are very dissimilar
in terms of the type of the arrhythmia (high rate of atrial
pacing, spontaneous or induced AF of variable duration),
the species studied (humans, dogs and goats) and the timing
of drug administration (before or after the arrhythmia
onset). These differences could account for the discordant
effects of verapamil on atrial electrophysiologic characteris-
tics. Moreover, even the results of clinical studies on the
effect of verapamil on AF termination and recurrence are
confounding. Some of them have shown no beneficial effect
of verapamil (12,13), whereas others (14,15) have demon-
strated a drug-induced reduction of the early recurrences of
the arrhythmia. This beneficial effect has been attributed to
a verapamil-mediated attenuation of the atrial electrical
remodeling. Therefore, because of the incomplete and
discordant reports on this subject, and in order to be close to
the clinical ground, the present study was designed to
evaluate the effects of oral administration of verapamil on
the atrial electrophysiologic characteristics in patients with
persistent AF. Thus, the following variables were evaluated
immediately after electrical cardioversion: atrial refractori-
ness, atrial refractoriness dispersion and atrial refractoriness
response to abrupt cycle length changes.
METHODS
Patient selection. The study included 30 consecutive pa-
tients with persistent AF (duration between 30 days and 3
years), referred to our Institute for cardioversion of the
arrhythmia. To be included in the study, the patients must
not have had a previous cardioversion attempt, either
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pharmacologic or electrical; they had to be off antiarrhyth-
mic drugs; and they had to be in New York Heart
Association functional class I or II, with no clinical or
instrumental signs of cardiac insufficiency. The eligible
patients were scheduled for a study protocol that included
internal electrical cardioversion followed by an electrophysi-
ologic study. Two patients with a contraindication to the
use of verapamil and two patients who refused to accept the
protocol were excluded from the study. The remaining 26
patients were randomly assigned to receive either no anti-
arrhythmic drugs (e.g., calcium antagonist, digoxin, beta-
blockers) or verapamil (240 mg/day) for three weeks before
endocavitary cardioversion. During this period, they were
also fully anticoagulated. The study was approved by our
Institutional Ethical Committee, and all the patients gave
their written, informed consent.
The diagnosis of AF was based on the surface electrocar-
diogram with the following criteria: presence of fluctuation
from baseline without regular P or F waves and totally
irregular RR intervals. These criteria had to be validated by
endocardial recordings showing variability of the beat-to-
beat cycle length, morphology and/or the amplitude of
recorded bipolar atrial electrograms (16).
Thyroid dysfunction had been ruled out in all patients. As
a rule, after completion of the protocol, all the patients were
treated with intravenous propafenone (2 mg/kg body
weight), followed by oral administration of the drug (600 to
750 mg/day).
Electrophysiologic study. Two catheters were used for
each patient; they were introduced in the same sheaths used
for the leads necessary for internal cardioversion. A standard
quadripolar lead with 2-mm spacing (Bard-USCI Inc.,
Lowell, Massachusetts) was positioned in the right atrium,
allowing contemporary recording of bipolar electrograms
from the distal and proximal pairs. In the right atrium, a
Franz catheter (EP Technologies, San Jose, California) was
also positioned. This was preferred because of its low pacing
threshold. The study was performed 5 min after low energy
internal cardioversion.
In each patient, up to five right atrial sites, depending on
the time needed for the procedure, were mapped in the 30°
left anterior oblique view. The mapped sites were the
following: mid lateral wall, low lateral wall, high lateral wall,
atrial roof and septum.
Follow-up. After the study, all the patients were treated
long term with propafenone (450 mg/day in three divided
doses). Moreover, the patients in the verapamil group
continued the drug at the same dosage. All the patients
visited the Outpatients Clinic one week, one month and six
months after the study.
Stimulation protocol. The stimulation protocol has been
previously described in detail (17). Briefly, the Franz cath-
eter was used for pacing by delivering a square wave of 2-ms
pulse duration at twice the stimulation threshold. At each
site, the ERP was measured at basic cycle lengths of 300,
400, 500 and 600 ms, and, when possible, in relation to the
sinus rate, at 700 ms, by the decremental extrastimulus
method using steps as short as 2 ms. The ERP was then
calculated after a short–long (eight basic drive beats at
300 ms followed by a 600-ms premature beat) and a
long–short (eight basic drive beats at 600 ms followed by a
300-ms premature beat) sequence and compared with the
ERP at basic cycle lengths of 600 and 300 ms, respectively.
The stimulation protocol was performed in random order
either clockwise (from the low lateral atrial wall to the
septum) or counterclockwise (from the septum to the low
lateral atrial wall). According to our protocol, the study was
stopped if pacing or programmed stimulation re-induced
AF or other sustained atrial arrhythmias, requiring cardio-
version. Patients were considered for data analysis only
when the protocol was completed at least in two sites;
otherwise, the patient was considered a dropout.
Statistical analysis. All data, unless otherwise noted, were
expressed as the mean value 6 SD. For intrapatient effects
of washout or verapamil, analysis of variance (ANOVA)
with repeated measures was used to compare mean values of
atrial ERP between the different basic cycle lengths of
pacing and after the short–long and the long–short se-
quence. When significant differences were detected, the data
were analyzed by paired the Student t test, and the proba-
bility value was corrected by multiplying it for the number of
comparisons (Bonferroni correction). The differences of the
measured numeric data between the washout and verapamil
groups were analyzed by the unpaired t test. The mean
values of ERP in different atrial sites within the same group
of treatment (e.g., verapamil or washout) were analyzed by
the unpaired Student t test, and the probability value was
corrected by Bonferroni correction. The dispersion of atrial
refractoriness (the longest ERP minus the shortest ERP)
was determined at the different basic cycle lengths.
Differences in categoric variables were analyzed by the
chi-square test with Yates’ correction or the Fisher exact
test. The relation between the mean ERP in each patient
and the duration of AF was studied by single linear
regression analysis. The results were considered to be
statistically significant at p , 0.05.
For each paced site, the linear correlation between the
ERPs and the corresponding pacing rates was calculated by
single linear regression analysis. The presence of normal or
abnormal refractoriness adaptation to rate and its degree
were also established by evaluating the slope values. Accord-
ing to the slope figures, the adaptation of the ERP to rate
was considered absent when the slope value was zero, and
inverted if its value was negative. For positive values
between 0.01 and 0.04, the adaptation was considered poor;
for values between 0.05 and 0.06, it was considered nearly
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normal; and for values $0.07, it was classified as normal
(17,18). The analysis was performed using the statistical
software GB-STAT (version 6.5.4).
RESULTS
Patients and paced sites. Three of the 26 patients selected
for the study (one in the washout group and two in the
verapamil group) were found to be in sinus rhythm at the
time of the scheduled cardioversion. In two of the remaining
23 patients (one in the washout group and one in the
verapamil group), internal cardioversion was followed by
immediate recurrence of AF. Therefore, 11 patients in the
washout group and 10 patients in the verapamil group were
studied. The study groups were comparable in terms of
baseline clinical characteristics (Table 1).
In two of the 21 patients, the study was stopped because
of the induction of sustained AF during the first or the
second stimulation sequence in the first paced site. One of
these patients was in washout and one was taking verapamil.
Thus, the stimulation protocol was carried out in 19
patients: 10 in washout and 9 taking verapamil. It was
performed in all five sites in 15 patients (eight in washout
and seven taking verapamil); in four sites in two patients
(one in washout and one taking verapamil); in three sites in
one patient in washout; and in two sites in one patient
taking verapamil—for a total of 88 sites. In two patients
(one in washout and one taking verapamil), the sequence at
the 700-ms cycle length was not performed because of the
higher sinus rate.
Table 2 reports the sites where the stimulation was
performed in both the washout and verapamil groups.
Refractoriness and adaptation of ERPs to rate. The
mean ERPs at the different stimulation cycle lengths, taking
into account all of the paced sites in both the washout and
verapamil groups, are reported in Table 3. The mean ERP
of the total group was significantly shorter in the verapamil
group than in the washout group (189.1 6 17.3 vs. 202.0 6
22.7 ms, p , 0.0001); this finding was present in all of the
stimulation cycles.
No relation was found between the duration of the AF
episode and the mean ERP, as studied in each patient (r 5
0.049, p 5 0.8).
As graphically shown in Figure 1, there was a linear
correlation between the mean atrial ERPs and the stimula-
tion rate in both groups (r 5 0.90 in the washout group and
r 5 0.94 in the verapamil group). The mean slope value was
0.07 6 0.03 in the washout group and 0.08 6 0.05 in the
verapamil group.
Considering the individual stimulation sites, slope values
$0.07 were present in 24 sites (51%) in the washout group
and 18 sites (44%) in the verapamil group; slope values
between 0.05 and 0.06 were found in 12 sites (26%) in the
washout group and 12 sites (29%) in the verapamil group;
slope values between 0.01 and 0.04 were found in 11 sites
(23%) in the washout group and 10 sites (24%) in the
verapamil group; and a slope value of 0 was found in one site
(3%) of one patient in the verapamil group. No negative
slope values were found in any site. Therefore, a normal or
nearly normal adaptation to the rate was present in 67 sites
(76%): 36 sites (77%) in the washout group and 31 sites
(75%) in the verapamil group (p 5 0.8).
Refractoriness dispersion. As shown in Table 4, the mean
ERPs were shorter in the lateral right atrial sites and in the
roof than in the septum, both in the washout and in the
verapamil groups; these differences reached statistical sig-
nificance when the septum was compared with the mid
lateral wall and the roof.
The spatial dispersion of refractoriness at the various
basic cycle lengths was similar between the two groups.
Effect of abrupt cycle length changes. The effects of the
long–short and short–long sequences on ERPs are shown in
Table 5.
In the washout group, the mean ERP after the long–short
sequence (basic cycle length of 600 ms followed by a beat at
300 ms) was significantly shorter than the ERP during
constant pacing at 300 ms (166.3 6 10.4 ms vs. 185.7 6
18.0 ms, p , 0.0001) (Fig. 2), implying an overshoot of the
adaptation of refractoriness to the preceding premature
beat. The overshoot was not bidirectional; in fact, no
difference was found between the atrial ERP during the
short–long sequence (basic cycle length of 300 ms followed
by a beat at 600 ms) and the ERP during constant pacing at
600 ms (201.3 6 18.7 ms vs. 209.4 6 21.4 ms, p 5 0.1)
(Fig. 2). In the verapamil group, the mean ERP after the
long–short sequence was also significantly different from the







Age (years) 62.7 6 11.3 61.7 6 12.2 NS
Gender (M/F) 6/5 6/4 NS
AF duration (days) 246.1 6 292.7 243.8 6 356.7 NS
LVDD (mm) 55.5 6 9.0 52.2 6 2.8 NS
LVSD (mm) 40.2 6 6.9 37.2 6 3.3 NS
LAD (mm) 42.9 6 3.8 41.1 6 6.2 NS
Ventricular rate
(beats/min)





AF only 3 2
Data are presented as the mean value 6 SD or number of patients.
AF 5 atrial fibrillation; F 5 female; LAD 5 left atrial diameter; LVDD 5 left
ventricular diastolic diameter; LVSD 5 left ventricular systolic diameter; M 5 male;
NS 5 not significant.
Table 2. Number of Sites Where the Stimulation Protocol Was
Performed in Patients in the Washout and Verapamil Groups
Lateral Roof Septum Total
Low Mid High
Washout 10 10 9 8 10 47
Verapamil 9 9 8 8 7 41
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ERP during constant pacing at 300 ms (168.5 6 12.3 ms vs.
175.2 6 13.2 ms, p , 0.03) (Fig. 3). However, the degree
of the overshoot was greater in the washout group than in
the verapamil group (mean ERP variation: 9.8% vs. 3.4%,
p , 0.0001). The mean ERP during the short–long
sequence and the ERP during constant pacing at 600 ms
were not significantly different in the verapamil group
(203.4 6 19.4 ms vs. 197.6 6 17.3 ms, p 5 0.2) (Fig. 3).
Follow-up. At one-month follow-up, AF recurrences were
observed in six patients (60%) in the washout group and in
two patients (20.2%) in the verapamil group (p 5 0.2),
whereas at six months, the recurrence rate was 70% (7 of 10
patients) in the washout group and 40.4% (4 of 9 patients)
in the verapamil group (p 5 0.5).
DISCUSSION
Main findings. In this study, we have demonstrated that
verapamil, when administered after AF onset, not only does
not prevent atrial electrical remodeling, but actually causes a
shortening of atrial ERPs. This behavior is opposite of that
described in the published data, both in animals and
humans, when the drug is given before the beginning of
either induced AF or high rate pacing. Moreover, long-term
verapamil administration has no effect on adaptation of
refractoriness to rate in this specific subset of patients, and
it does not seem to have any effect on refractoriness
dispersion. Furthermore, the abnormal overshoot in refrac-
toriness adaptation after a long–short sequence that is
present in patients in washout became reduced in patients
treated with the drug.
Effects of high rates on transmembrane ionic currents.
Previous experimental studies have demonstrated that rapid
and irregular depolarizations can increase cytosolic Ca21 in
cardiac myocytes of many different species (19,20). In turn,
intracellular Ca21 overload was shown to reduce both the
L-type Ca21 current (ICa) (21,22) and the transient outward
K1 current (Ito) both in atrial and ventricular myocytes
(23–25). Moreover, in atrial appendages of patients with
chronic AF, there was a downregulation of the expression of
the alpha-subunit of the Kv 1.5 protein, which is responsible
for the ultrarapid component of the delayed rectifier current
(IKur), leading to a reduction of the outward K
1 current
densities (26). Indeed, it is worth noting that after rapid
and/or irregular depolarizations, the degree of reduction in
the specific current flows differs in the two cardiac chambers
(27,28). In the atria, a reduction in ICa is prevalent,
accounting for the shortening of action potential and
refractoriness duration, whereas in the ventricle, the reduc-
tion in Ito is more important, leading to a prolongation of
the aforementioned variables.
Effect of verapamil on atrial ERPs. Several studies have
been performed to evaluate whether the L-type calcium
Figure 1. Relation between ERPs and pacing cycle in total study group: patients in washout and patients pretreated with verapamil. A linear correlation
between refractoriness and pacing cycle, with a clear adaptation of ERPs to rate, is present in both patients in washout and patients pretreated with
verapamil.
Table 3. Refractory Periods (mean 6 SD of All Paced Sites) at Each Basic Cycle Length in
Washout and Verapamil Groups
Basic Cycle Length (ms)
300 400 500 600 700 All
Washout 185 6 18.0 197.4 6 21.2 203.9 6 21.4 209.4 6 21.2 215.2 6 23.2 202.0 6 22.7
Verapamil 175.2 6 13.2 183.4 6 14.2 190.9 6 16.7 197.6 6 17.3 201.0 6 15.0 189.1 6 17.3
p Value 0.003 0.001 0.003 0.007 0.003 0.0001
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channel blocker verapamil could counteract atrial refracto-
riness changes induced by high atrial rates. Tieleman et al.
(5) showed in goats that electrical remodeling of the atrium
induced by rapid atrial pacing was significantly attenuated
by verapamil infusion started 4 h before the stimulation.
Goette et al. (6) reported that in dogs subjected to 7 h of
atrial pacing at 800 beats/min, atrial electrical remodeling
was blocked by verapamil administered as an intravenous
bolus (followed by continuous infusion) 30 min before the
high frequency pacing. Daoud et al. (7) and Yu et al. (8)
reported that in humans, ERP shortening, after brief
episodes of pacing-induced AF, was markedly attenuated by
verapamil infusion given before the induction of the ar-
rhythmia. On the basis of these results, it was suggested that
the drug could be clinically effective in preventing immedi-
ate recurrence of AF after cardioversion or in reducing the
duration of AF paroxysms (5–8).
Our findings were substantially different: verapamil,
when administered after the onset of persistent AF, actually
shortened the postcardioversion atrial ERPs, thus possibly
reducing the chances of spontaneous termination of the
arrhythmia and increasing the likelihood of its early recur-
rence after cardioversion.
These opposite findings could be explained by the differ-
ent timing of the drug administration in relation to the
onset of the arrhythmia. It could be that verapamil may
prevent the electrical remodeling when given before or
shortly after the onset of high atrial rates (rapid pacing or
AF), but it is totally ineffective or even has a paradoxic
worsening effect when given after high atrial rates have
already been established and electrical (and possibly struc-
tural) remodeling is already present. In support of this
hypothesis, Ramanna et al. (10) observed that in patients
with chronic AF, early infusion of verapamil determined a
shortening of the mean fibrillatory interval, an index of the
local refractory period, whereas Duytschaever et al. (11), in
a goat model of paroxysmal AF, observed that verapamil
infusion shortened the AF cycle length and changed parox-
ysmal into chronic AF when given intravenously after 24 h
of electrically maintained AF. Recently, Sato et al. (29),
when administering oral verapamil to patients with chronic
AF, found no difference in their atrial refractory periods
after cardioversion, as compared with patients in washout.
The recovery from electrical remodeling was indeed delayed
in patients taking verapamil. On the basis of these results, it
is conceivable that verapamil could have different biochem-
ical effects on high rate–activated atrial cells in relation to
the timing of its administration. When administered before
high rate cell stimulation, the drug could prevent calcium
overload and the consequent reduction of ICa. This effect
probably outweighs the ICa reduction because of the direct
effect of the drug on sarcolemmal L-type calcium channels
(30), and thus prevents ERP shortening. In contrast, when
electrical remodeling has already occurred, verapamil could
not totally reverse the calcium overload, and the prevalent
effect of the drug could be a further reduction of ICa, owing
to the direct action of verapamil on the L-type calcium
channels. This leads to a further shortening of the plateau
phase of the monophasic action potential duration and,
hence, of refractoriness. Moreover, it is known that al-
though short-lasting high rate depolarization shortens
ERPs by direct Ca21-induced ICa inhibition (31), in pa-
tients with long-lasting AF, a further contribution to
persistent ERP shortening is also caused by a decrease in
messenger ribonucleic acid levels of the L-type calcium
Figure 2. Mean ERP after constant pacing (300, 400, 500, 600 and
700 ms) and after long–short (600 to 300 ms) and short–long (300 to
600 ms) sequences in patients in washouts. Mean ERP during the
long–short sequence is significantly shorter than ERP at 300 ms. This
“overshoot” is not bidirectional, because no difference is present between
ERP during the short–long sequence and ERP at 600 ms.
Table 4. Atrial Effective Refractory Periods in Different Right







Washout 206 6 14 196 6 24* 199 6 24 194 6 22* 212 6 26
Verapamil 189 6 16 185 6 18* 189 6 21 187 6 13† 198 6 19
*p , 0.01 vs. septum. †p , 0.05 vs. septum. Data are presented as the mean
value 6 SD.
Table 5. Refractory Periods at Constant Pacing of 300 and 600 ms Compared With







n 300 ms 600–300 ms 300–600 ms p Value
Washout 47 185.7 6 18.0 166.3 6 10.4 0.0001 209.4 6 21.4 201.3 6 18.7 0.1
Verapamil 41 175.2 6 13.2 168.5 6 12.3 0.03 197.6 6 17.3 203.4 6 19.4 0.2
All 88 180.8 6 16.7 167.6 6 11.5 0.0001 209.0 6 21.1 202.5 6 18.9 0.08
Data are presented as the mean value 6 SD, unless otherwise indicated.
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channels, leading to downregulation of the channels’ density
(32). In this case, a more marked effect on repolarization
could be expected, because there is a direct drug-mediated
effect of ICa on a reduced number of L-type channels.
However, keep in mind that the difference in refractori-
ness between the washout and verapamil groups could be
explained, at least in part, by increased refractoriness in the
washout group, related to impaired left ventricular function
due to higher ventricular rates, as reported by Li et al. (33)
in the setting of heart failure at high rates in dogs.
Nevertheless, none of our patients had clinical signs of heart
failure, and recently left ventricular dysfunction was found
to have no effect on atrial refractoriness in dogs (34).
Effect of verapamil on ERP adaptation to rate. Accord-
ing to the slope values, a normal or nearly normal adaptation
to the stimulation rate was found in the majority of atrial
sites, both in the washout and verapamil groups. In fact, no
significant difference was found in the mean slope value
between the two groups. This results are in agreement with
previous reports of our group, which have shown, after
cardioversion of persistent AF, a normal or nearly normal
refractoriness adaptation to the stimulation cycle, both in
patients in washout and in patients pretreated with amio-
darone (17). The fact that the patients pretreated with
verapamil have a similar behavior confirms these results and
suggests that verapamil has no effect on the ERP adaptation
to rate, contrary to what has been previously reported in
animals (5). In fact, the number of sites with normal, nearly
normal, poor and no adaptation to rate was similar in the
washout and verapamil groups.
Effects of verapamil on refractoriness dispersion. In our
study, the ERPs were found to be shorter in the lateral right
atrial wall and in the roof than in the septum, both in the
washout and verapamil groups. Moreover, the degree of
refractoriness dispersion was not significantly different be-
tween the two groups, implying that pretreatment with
verapamil does not affect the inhomogeneity of recovery of
excitability within the right atrium.
Our results are somehow different from those of a recent
report showing that verapamil infusion in patients with
chronic AF increased refractoriness dispersion between the
lateral wall and the right atrial appendage (10). In this study,
refractoriness dispersion was evaluated by calculating the
coefficient of dispersion (standard deviation of all mean
fibrillatory intervals expressed as a percentage of the overall
mean fibrillatory interval). The differences in the mode of
drug administration in the right atrial sites studied and in
the methods for determination of refractoriness dispersion
could account for the different results.
Effect of abrupt cycle length changes on refractoriness.
It is known that the ERP of normal atrial myocardium
abruptly and appropriately adjusts to the duration of the last
cycle (35,36). We have previously demonstrated (17) that
after cardioversion of persistent AF, atrial refractoriness
shows an abnormal overshoot in adaptation after a long–
short sequence. This phenomenon may have clinical rele-
vance because it could contribute to the frequent recurrence
of the arrhythmia in the first days after cardioversion and
has been confirmed in the patients in washout in the present
study. Moreover, an abnormal overshoot in atrial refracto-
riness adaptation after a long–short sequence was found also
in patients pretreated with verapamil before cardioversion.
However, the degree of the overshoot was less prominent,
implying a possible favorable action of the drug on this
abnormal behavior.
Follow-up. The patients treated with both propafenone
and verapamil had less recurrence of AF as compared with
those patients treated with propafenone alone, but the
numbers are too small to permit any significant conclusion.
The study, however, was not designed as a follow-up study.
Clinical implications. The results of clinical studies on the
effect of verapamil on AF termination and on its recurrence
rate are not uniform in the published data. A recent study
(14) concluded that treatment with drugs that reduce Ca21
entry decreases the recurrence rate of the arrhythmia.
Actually, it was a nonrandomized, retrospective study, and
patients in the control group were taking digoxin in the
majority of cases; therefore, it is not possible to determine
whether the lower recurrence rate observed in the treated
group was the consequence of the administration of calcium
antagonist drugs or the effect of a possible digoxin proar-
rhythmic action in the other group. More recently, De
Simone et al. (37) demonstrated that the addition of
verapamil to propafenone three days before cardioversion in
patients with persistent AF reduced the incidence of early
recurrence of AF, as compared with propafenone alone. In
contrast, other studies have shown no effect (13) or a
worsening action of verapamil on AF duration and recur-
rences (12).
The main result of our study—further shortening of atrial
ERPs—suggests that verapamil should favor rather than
Figure 3. Mean ERP after constant pacing (300, 400, 500, 600 and
700 ms) and after long–short (600 to 300 ms) and short–long (300 to
600 ms) sequences in patients pretreated with verapamil. Mean ERP
during the long–short sequence is significantly shorter than ERP at 300 ms
in these patients. However, the degree of this “overshoot” is smaller than
that observed in patients in washout. The “overshoot” is not bidirectional,
because no difference is present between ERP during the short–long
sequence and ERP at 600 ms.
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prevent the recurrence of the arrhythmia after cardioversion
in patients with persistent AF. However, it has to be
considered that verapamil could theoretically exert even
favorable effects in patients with AF: it could determine the
reversal of the structural and ultrastructural cellular changes
(6,38,39) and of the atrial morphologic modifications (40)
related to the development of an atrial tachymyopathy.
Recently, Haissaguerre et al. (41) have shown that radio-
frequency ablation of triggering atrial ectopic beats origi-
nating from foci located in the pulmonary veins eliminated
AF recurrences in 62% of the patients. Verapamil could
suppress the firing of the atrial foci, triggering AF recur-
rences, thanks to its action on abnormal automaticity and on
early and delayed afterdepolarization (42). Moreover, our
finding that the drug reduces the degree of the overshoot
after a long–short sequence could have some protective role.
Therefore, future randomized, prospective studies are
needed to establish the actual effect of verapamil on AF
recurrences and the electrophysiologic mechanisms ac-
counting for this effect.
Study limitations. First, our results are limited to the right
atrium, because no left atrial site was considered in the
study. Second, the protocol was discontinued in patients
with re-induced AF, so that patients with the higher atrial
vulnerability were excluded. Nevertheless, the protocol was
completed in at least two sites in 90% of the studied
patients, and therefore our observation is applicable to the
majority of patients with persistent AF. Third, conditioning
pacing trains, which have been demonstrated to be useful in
improving the reproducibility of ventricular ERPs, were not
used in this study because of the long duration of the
stimulation protocol.
Reprint requests and correspondence: Dr. Claudio Pandozi, Via
Madonna di Fatima 24, 00147 Rome, Italy. E-mail: m.santini@
rmnet.it.
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